SQI Diagnostics Inc. and Algorithme Pharma announced that they are using SQI's Ig_Plex(TM) multiplexing technology to develop a multiplex proof of concept assay targeted at immunogenicity testing of heparin and heparin-based low molecular weight (LMWT) biosimilar compounds. SQI and Algorithme will present the results of the proof of concept studies at the upcoming 14th Annual Immunogenicity for Biotherapeutics Conference in Baltimore 18-20 March, in a presentation titled 'A Novel Approach for Multiplexed Detection, Isotyping, and Quantitation of IgG, IgA, and IgM PF4/Heparin Antibodies using SQI Diagnostics' Ig_Plex(TM) Technology'.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- CAD | -.--% |
|
-100.00% | -100.00% |
2023 | SQI Diagnostics Announces Resignation of Wilmot L. Matthews as Director | CI |
2023 | Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc | CI |
1st Jan change | Capi. | |
---|---|---|
-100.00% | 4.49M | |
+3.26% | 209B | |
+6.55% | 183B | |
+31.66% | 158B | |
+34.32% | 114B | |
+5.13% | 67.29B | |
+19.33% | 54.83B | |
-3.30% | 46.88B | |
-4.84% | 38.58B | |
+3.83% | 36.65B |
- Stock Market
- Equities
- SQD.H Stock
- News SQI Diagnostics Inc.
- SQI Diagnostics Inc. and Algorithme Pharma Partner to Develop Multiplex Heparin Immunogenicity Assay